cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...

A key opinion leader explains how acquired TTP is diagnosed, with a focus on the use of ADAMTS13 testing. X. Long Zheng, MD, PhD: How do you actually diagnose TTP [thrombotic thrombocytopenic purpura] ...

− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of Evidence ...

Credit: Getty Images. Congenital thrombotic thrombocytopenic purpura is an ADAMTS13 deficiency disorder. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP) cTTP Is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder ...

Hepatic platelet accumulation in PA-ILI was confirmed in both patients and mice. Deficiency of ADAMTS13 plays a critical role in platelet accumulation in PA-ILI, suggesting that ADAMTS13 could be a ...

In the pregnancy reported here (the mother’s fifth pregnancy), the mother had been referred for hematology evaluation in the second trimester; at that time, fetal growth and a scan of the uterine ...

Including biomarkers for non-ADAMTS13 in routine clinical testing could benefit diagnosis and follow-up in patients with immune-mediated thrombotic thrombocytopenic purpura (TTP). Patients with immune ...

Congenital thrombotic thrombocytopenic purpura results from severe hereditary deficiency of ADAMTS13. Prophylactic approaches with an improved safety profile are needed. New research findings are ...

Pyrrolizidine alkaloids (PAs), widely distributed in plants, are known to induce liver failure. Hepatic platelet accumulation has been reported during the progression of PA-induced liver injury ...